Transarterial therapies for hepatocellular carcinoma (HCC): a long way towards standardization

Free article

Comment

Emmanuel A Tsochatzis et al. J Hepatol. 2013 Jan.

Free article

. 2013 Jan;58(1):194.

doi: 10.1016/j.jhep.2012.08.028. Epub 2012 Oct 6.

No abstract available

Comment in

Reply to: "Transarterial therapies for hepatocellular carcinoma (HCC): a long way towards standardization".
Park JW, Kim HB, Lee IJ. Park JW, et al. J Hepatol. 2013 Jan;58(1):195. doi: 10.1016/j.jhep.2012.09.033. Epub 2012 Oct 6. J Hepatol. 2013. PMID: 23046675 No abstract available.

Phase II study of concurrent transarterial chemoembolization and sorafenib in patients with unresectable hepatocellular carcinoma.
Park JW, Koh YH, Kim HB, Kim HY, An S, Choi JI, Woo SM, Nam BH. Park JW, et al. J Hepatol. 2012 Jun;56(6):1336-42. doi: 10.1016/j.jhep.2012.01.006. Epub 2012 Feb 4. J Hepatol. 2012. PMID: 22314421 Clinical Trial.
Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (TACE) using Drug Eluting Beads. Implications for clinical practice and trial design.
Burrel M, Reig M, Forner A, Barrufet M, de Lope CR, Tremosini S, Ayuso C, Llovet JM, Real MI, Bruix J. Burrel M, et al. J Hepatol. 2012 Jun;56(6):1330-5. doi: 10.1016/j.jhep.2012.01.008. Epub 2012 Feb 5. J Hepatol. 2012. PMID: 22314428 Free PMC article.